Safety and Efficacy Study of Gamaline+Hipericin in PMS (GH)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2011 by Phytopharm Consulting Brazil.
Recruitment status was  Recruiting
Herbarium Laboratorio Botanico Ltda
Federal University of Health Science of Porto Alegre
Information provided by (Responsible Party):
Phytopharm Consulting Brazil Identifier:
First received: January 24, 2011
Last updated: November 25, 2011
Last verified: November 2011
GAMALINE is already register for PMS and HIPERICIN as antidepressive drug. Both plant extracts. The investigators will try the mixture and see if the vasomotor symptoms will disappear. The investigators expect that together all symptoms will be covered better than Gamaline alone. The investigators will run for 180 days measuring at T0, T1 and T6 (starting point, 30 days and 180 days).

Hot Flashes

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Phase IV Study of Combined GAMALINE and HIPERICIN for Treating Pre-Menstrual Syndrome and Vasomotor Symptoms

Resource links provided by NLM:

Further study details as provided by Phytopharm Consulting Brazil:

Estimated Enrollment: 240
Study Start Date: January 2011
Estimated Study Completion Date: February 2012
Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
1 - Gamaline+Hipericin - fertile women
2- Gamaline+Hipericin - climateric women
3- Gamaline- control - fertile women
4 - Gamaline control - climateric women

Detailed Description:
This protocol wants to show the advantages for the mixture GAMALINE 900mg+HIPERICIN 300mg - 2 herbal extracts for PMS treatment against the individual use of GAMALINE

Ages Eligible for Study:   25 Years to 55 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Only women from 25 to 55 years old with PMS symptoms

Inclusion Criteria:

  • climacteric pre-menopausal women between 45 e 55 anos
  • women between 25 e 44 anos

Exclusion Criteria:

  • Age inferior 25 anos or superior 55 anos and/or decline invitation.
  • Patients pos-menopause
  • Under hormone therapy
  • Thyroid disease
  • Under psychiatric therapy or medication
  • History for allergies and hypersensitivity to one or both extracts
  • Breast feeding or pregnancy
  • No knowledge for writing and/or reading
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01283568

Contact: Carla Vanin, MD MSc PhD +55 51 99628061

Ambulatório de Ginecologia e Obstetrícia ISCMPA Recruiting
Porto Alegre, RS, Brazil, 90020-090
Contact: Carla Vanin, MD MSc PhD    +55 51 32148080   
Sub-Investigator: Raquel P Dibi, MD MSc         
Principal Investigator: Carla Vanin, MD MSc PhD         
Sponsors and Collaborators
Phytopharm Consulting Brazil
Herbarium Laboratorio Botanico Ltda
Federal University of Health Science of Porto Alegre
Study Chair: Karla F Deud José, Pharm PhD Phytopharm Consulting Brazil -
  More Information

No publications provided

Responsible Party: Phytopharm Consulting Brazil Identifier: NCT01283568     History of Changes
Study First Received: January 24, 2011
Last Updated: November 25, 2011
Health Authority: Brazil: National Committee of Ethics in Research
Brazil: National Health Surveillance Agency

Keywords provided by Phytopharm Consulting Brazil:
PMS, climacteric, depression processed this record on November 27, 2015